Sniff your way slim? early test for Weight-Loss nasal spray begins
NCT ID NCT07465965
Summary
This is an early-stage study to check the safety and how the body processes a new nasal spray version of a weight loss medication called semaglutide. It will involve 60 overweight or obese adults who will receive a single dose. The main goal is to see how safe the spray is and how it behaves in the body compared to a placebo and an existing injectable version.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Frontage Clinical Services, Inc.
RECRUITINGSecaucus, New Jersey, 07094, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.